Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average – What’s Next?

Chimerix, Inc. (NASDAQ:CMRX) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.91 and traded as high as $1.00. Chimerix shares last traded at $0.99, with a volume of 207,019 shares trading hands.

Analyst Ratings Changes

A number of analysts have weighed in on CMRX shares. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Chimerix in a research report on Wednesday, August 14th. Finally, StockNews.com raised Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Stock Up 2.1 %

The business has a 50-day simple moving average of $0.90 and a two-hundred day simple moving average of $0.91. The company has a market cap of $88.74 million, a price-to-earnings ratio of -1.04 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same period in the prior year, the firm posted ($0.21) EPS. As a group, equities analysts anticipate that Chimerix, Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Chimerix

Large investors have recently made changes to their positions in the business. Marshall Wace LLP acquired a new position in shares of Chimerix during the 2nd quarter worth about $137,000. Valeo Financial Advisors LLC raised its holdings in Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 69,505 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Koshinski Asset Management Inc. acquired a new position in Chimerix in the 1st quarter valued at approximately $42,000. Finally, Marquette Asset Management LLC raised its holdings in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.